Central European Journal of Sport Sciences and Medicine

ISSN: 2300-9705     eISSN: 2353-2807    OAI    DOI: 10.18276/cej.2015.3-03
CC BY-SA   Open Access   DOAJ  DOAJ

Lista wydań / Vol. 11, No. 3/2015
Post-transplant Metabolic Syndrome (PTMS) after Liver Transplantation –Review of the Literature

Autorzy: Katarzyna Kotarska
Faculty of Physical Culture and Health Promotion, University of Szczecin, Poland

Joanna Raszeja-Wyszomirska
Hepatology and Internal Medicine Unit, Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Poland
Słowa kluczowe: metabolic syndrome liver transplantation
Data publikacji całości:2015
Liczba stron:9 (29-37)
Cited-by (Crossref) ?:


Liver transplant provides a definitive therapeutic measure for patients with chronic and acute liver diseases. Apart from the improvement of overall health, an organ transplant entails several metabolic complications. They are multi-agent and depend, among others, on the function of organ being transplanted, adverse effects of immunosuppression being applied, organ complications induced by failure of the organ being transplanted, current treatment, concomitant diseases and consequences of the acute and chronic rejection processes. Improvements in surgical techniques, peritransplant intensive care, and immunosuppressive regimens have resulted in significant improvements in short-term survival. Focus has now shifted to address long-term outcomes of liver transplantation. Therefore, this paper presents the current review of literature referring to specificity of the prevalence of metabolic syndrome and its complications in patients after liver transplantation.
Pobierz plik

Plik artykułu


1.Albeldawi M., Aggarwal A., Madhwal S., Cywinski J., Lopez R., Eghtesad B., Zein N.N. Cumulative risk of cardiovascular events after orthotopic liver transplantation. Liver Transpl. 2012; 18: 370–375.
2.Balamuthusamy S., Srinivasan L., Verma M., Adigopula S., Jalandhara N., Hathiwala S., Smith E. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis. Am Heart J. 2008; 155: 7
3.Bianchi G., Marchesini G., Marzocchi R., Pinna A.D., Zoli M. Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. Liver Transpl. 2008; 14: 1648–1654.
4.Charlton M. Obesity, hyperlipidemia, and metabolic syndrome. Liver Transpl. 2009; 15 Suppl 2: 83–89.
5.Contos M.J., Cales W., Sterling R.K., Luketic V.A., Shiffman M.L., Mills A.S., Fisher R.A., Ham J., Sanyal A.J. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl. 2001; 7: 363–3
6.Epstein S.K., Freeman R.B., Khayat A., Unterborn J.N., Pratt D.S., Kaplan M.M. Aerobic capacity is associated with 100-day outcome after hepatic transplantation. Liver Transpl. 2004; 10: 418–424.
7.Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285: 2486–2497.
8.Faenza A., Fuga G., Nardo B., Donati G., Cianciolo G., Scolari M.P., Stefoni S. Metabolic syndrome after kidney transplantation. Transplant Proc. 2007; 39: 1843–1846.
9.Grundy S.M., Balady G.J., Criqui M.H., Fletcher G., Greenland P., Hiratzka L.F., Houston-Miller N., Kris-Etherton P., Krumholz H.M., LaRosa J., Ockene I.S., Pearson T.A., Reed J., Washington R., Smith S.C., Jr. Primary prevention of coronary heart disease
10.Guckelberger O. Long-term medical comorbidities and their management: hypertension/cardiovascular disease. Liver Transpl. 2009; 15 Suppl 2: 75–78.
11.Hakeam H.A., Al-Jedai A.H., Raza S.M., Hamawi K. Sirolimus induced dyslipidemia in tacrolimus based vs. tacrolimus free immunosuppressive regimens in renal transplant recipients. Ann Transplant. 2008; 13: 46–53.
12.Hanouneh I.A., Feldstein A.E., McCullough A.J., Miller C., Aucejo F., Yerian L., Lopez R., Zein N.N. The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl. 2008; 14: 1287–1293.
13.Hryniewiecka E., Zegarska J., Paczek L. Arterial hypertension in liver transplant recipients. Transplant Proc. 2011; 43: 3029–3034.
14.Johnston S.D., Morris J.K., Cramb R., Gunson B.K., Neuberger J. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation. 2002; 73: 901–906.
15.Krasnoff J.B., Mathias R., Rosenthal P., Painter P.L. The comprehensive assessment of physical fitness in children following kidney and liver transplantation.Transplantation. 2006; 82: 211–217.
16.Laish I., Braun M., Mor E., Sulkes J., Harif Y., Ben A.Z. Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events. Liver Transpl. 2011; 17: 15–22.
17.Laryea M., Watt K.D., Molinari M., Walsh M.J., McAlister V.C., Marotta P.J., Nashan B., Peltekian K.M. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl. 2007; 13: 1109–1114.
18.Leithead J.A., Ferguson J.W., Hayes P.C. Modifiable patient factors are associated with the late decline in renal function following liver transplantation. Clin Transplant. 2012; 26: E316–E323.
19.Lim L.G., Cheng C.L., Wee A., Lim S.G., Lee Y.M., Sutedja D.S., Da C.M,. Prabhakaran K., Wai C.T. Prevalence and clinical associations of posttransplant fatty liver disease. Liver Int. 2007; 27: 76–80.
20.Madhwal S., Atreja A., Albeldawdi M., Lopez R., Post A., Costa M.A. Is liver transplantation a risk factor for cardiovascular disease? A meta-analysis of observational studies. Liver Transpl. 2012; 18: 1140–1146.
21.Malik S.M., Devera M.E., Fontes P., Shaikh O., Sasatomi E., Ahmad J. Recurrent disease following liver transplantation for nonalcoholic steatohepatitis cirrhosis. Liver Transpl. 2009; 15: 1843–1851.
22.Mells G., Neuberger J. Long-term care of the liver allograft recipient. Semin Liver Dis. 2009; 29: 102–120.
23.Miller L.W. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant. 2002; 2: 807–818.
24.Ong J., Younossi Z.M., Reddy V., Price L.L., Gramlich T., Mayes J., Boparai N. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl. 2001; 7: 797–801.
25.Pagadala M., Dasarathy S., Eghtesad B., McCullough A.J. Posttransplant metabolic syndrome: an epidemic waiting to happen. Liver Transpl. 2009; 15: 1662–1670.
26.Pageaux G.P., Calmus Y., Boillot O., Ducerf C., Vanlemmens C., Boudjema K., Samuel D. Steroid withdrawal at day 14 after liver transplantation: a double-blind, placebo-controlled study. Liver Transpl. 2004; 10: 1454–1460.
27.Parekh J., Corley D.A., Feng S. Diabetes, hypertension and hyperlipidemia: prevalence over time and impact on long-term survival after liver transplantation. Am J Transplant. 2012; 12: 2181–2187.
28.Patil D.T., Yerian L.M. Evolution of nonalcoholic fatty liver disease recurrence after liver transplantation. Liver Transpl. 2012; 18: 1147–1153.
29.Pruthi J., Medkiff K.A., Esrason K.T., Donovan J.A. Yoshida E.M., Erb S.R., Steinbrecher U.P., Fong T.L. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl. 2001; 7: 811–815.
30.Reuben A. Long-term management of the liver transplant patient: diabetes, hyperlipidemia, and obesity. Liver Transpl. 2001; 7: S13–S21.
31.Rothbaum P.E., Lau A., Rhee S., Roberts J.P., Rosenthal P. Posttransplant metabolic syndrome in children and adolescents after liver transplantation: a systematic review. Liver Transpl. 2012; 18: 1009–1028.
32.Seo S., Maganti K., Khehra M., Ramsamooj R., Tsodikov A., Bowlus C., McVicar J., Zern M., Torok N. De novo nonalcoholic fatty liver disease after liver transplantation. Liver Transpl. 2007; 13: 844–847.
33.Soveri I., Abedini S., Holdaas H., Jardine A., Eriksson N., Fellstrom B. Metabolic syndrome and cardiovascular risk in renal transplant recipients: effects of statin treatment. Clin Transplant. 2009; 23: 914–920.
34.Sprinzl M.F., Weinmann A., Lohse N., Tonissen H., Koch S., Schattenberg J., Hoppe-Lotichius M., Zimmermann T., Galle P.R., Hansen T., Otto G, Schuchmann M. Metabolic syndrome and its association with fatty liver disease after orthotopic liver transplantat
35.Textor S.C., Taler S.J., Canzanello V.J., Schwartz L., Augustine J.E. Posttransplantation hypertension related to calcineurin inhibitors. Liver Transpl. 2000; 6: 521–530.
36.Tinti F., Mitterhofer A.P., Muiesan P. Liver transplantation: role of immunosuppression, renal dysfunction and cardiovascular risk factors. Minerva Chir. 2012; 67: 1–13.
37.Tomas M.T., Santa-Clara H., Bruno P.M., Monteiro E., Carrolo M., Barroso E., Sardinha L.B., Fernhall B. The Impact of Exercise Training on Liver Transplanted Familial Amyloidotic Polyneuropathy (FAP) Patients. Transplantation. 2013; 95: 372–377.
38.Tomas M.T., Santa-Clara H., Monteiro E., Barroso E., Sardinha L.B. Effects of an exercise training program in physical condition after liver transplantation in familial amyloidotic polyneuropathy: a case report. Transplant Proc. 2011; 43: 257–258.
39.Vanwagner L.B., Bhave M., Te H.S., Feinglass J., Alvarez L., Rinella M.E. Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events. Hepatology. 2012; 56: 1741–1750.
40.Wawrzynowicz-Syczewska M., Karpinska E., Jurczyk K., Laurans L., Boron-Kaczmarska A. Risk factors and dynamics of weight gain in patients after liver transplantation. Ann Transplant. 2009; 14: 45–50.